Furadantin Side Effects
Generic name: nitrofurantoin
Note: This document contains side effect information about nitrofurantoin. Some of the dosage forms listed on this page may not apply to the brand name Furadantin.
Some side effects of Furadantin may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to nitrofurantoin: oral capsule, oral suspension, oral tablet
Along with its needed effects, nitrofurantoin (the active ingredient contained in Furadantin) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking nitrofurantoin:More common
- Changes in facial skin color
- chest pain
- general feeling of discomfort or illness
- joint or muscle pain
- shortness of breath
- skin rash
- sudden trouble in swallowing or breathing
- swelling of the face, mouth, hands, or feet
- troubled breathing
- Black, tarry stools
- blood in the urine or stools
- burning, numbness, tingling, or painful sensations
- pinpoint red spots on the skin
- sore throat
- unsteadiness or awkwardness
- unusual bleeding or bruising
- unusual tiredness or weakness
- weakness in the arms, hands, legs, or feet
- Abdominal or stomach pain
- blistering, peeling, or loosening of the skin and mucous membranes
- blue-yellow color blindness
- bluish color of the fingernails, lips, skin, palms, or nail beds
- blurred vision or loss of vision, with or without eye pain
- bulging soft spot on the head of an infant
- change in the ability to see colors, especially blue or yellow
- cracks in the skin
- darkening of the urine
- decreased vision
- diarrhea, watery and severe, which may also be bloody
- eye pain
- general tiredness and weakness
- light-colored stools
- loss of appetite
- loss of heat from the body
- mental depression
- mood or mental changes
- nausea or vomiting
- pale skin
- pale stools
- red skin lesions, often with a purple center
- red, irritated eyes
- red, swollen skin
- red, thickened, or scaly skin
- skin rash
- sores, ulcers, or white spots on the lips or in the mouth
- swollen or painful glands
- tenderness of salivary glands
- unpleasant breath odor
- upper right abdominal pain
- visual changes
- vomiting of blood
- wheezing or tightness in the chest
- yellow eyes or skin
Some side effects of nitrofurantoin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Dizziness or lightheadedness
- feeling of constant movement of self or surroundings
- lack or loss of strength
- loss of hair, temporary
- sensation of spinning
- uncontrolled eye movements
For Healthcare Professionals
Applies to nitrofurantoin: compounding powder, oral capsule, oral suspension
Common (1% to 10%): Nausea (8%), flatulence (1.5%)
Uncommon (0.1% to 1%): Diarrhea (less than 1%), dyspepsia (less than 1%), abdominal pain (less than 1%), constipation (less than 1%), emesis (less than 1%)
Rare (less than 0.1%): Parotitis, pseudomembranous colitis
Frequency not reported: Anorexia, sialadenitis, pancreatitis
Nausea, emesis, and anorexia occurred most often; abdominal pain and diarrhea were less common. These side effects were dose-related (minimized by dose reduction) and occurred more frequently with Furadantin(R), the crystalline form of the drug. Administration of the drug with food reduced gastrointestinal intolerance.
Comparative studies of the gastrointestinal side effects of the crystalline form (Furadantin[R]) and the macrocrystalline form (Macrodantin[R]) reported up to 34% gastrointestinal intolerance with the crystalline form and up to 13% with the macrocrystalline form. In patients who were unable to tolerate Furadantin(R), 80% were able to tolerate Macrodantin(R).
The onset of pseudomembranous colitis symptoms has been reported during and after antimicrobial therapy.
Pancreatitis due to nitrofurantoin has been reported. In one case, the patient experienced cholestatic jaundice secondary to edema of the pancreas.
Respiratory system side effects have included both acute and chronic pulmonary toxicity. Acute toxicity has occurred from within a few hours to 3 weeks after therapy was started and consisted of dyspnea, cough, fever, and chills. Chronic toxicity has generally occurred after 6 months of therapy and has presented with an insidious onset of dyspnea, cough, malaise, and fatigue.
Respiratory side effects associated with nitrofurantoin (the active ingredient contained in Furadantin) therapy have occurred as both acute and chronic events. Acute pulmonary reactions have manifested as a type of hypersensitivity, and have occurred rapidly in patients who were previously sensitized. Of one group of 447 pulmonary reactions reported, 89% were of the acute type. Patients commonly had eosinophilia. Lung changes generally included alveolar infiltrates. Alveolar hemorrhage and death have been reported. Symptoms generally resolved within 24 to 48 hours after nitrofurantoin was discontinued.
Chronic pulmonary reactions occurred after 6 months of therapy and were generally more severe. Biopsy often revealed interstitial fibrosis. Eosinophilia was less common. Positive antinuclear antibodies were reported in up to 66% of patients, and patients commonly exhibited abnormal liver function tests. Resolution of symptoms usually occurred over a few months, although deaths have been reported. It has been suggested that the mechanism of this reaction is a combination of drug toxicity and an immune reaction.
Uncommon (0.1% to 1%): Acute pulmonary hypersensitivity reaction (less than 1%)
Rare (less than 0.1%): Cyanosis
Frequency not reported: Pulmonary hypersensitivity reactions (chronic and subacute), chronic pulmonary reactions (symptoms include malaise, exertional dyspnea, cough, altered pulmonary function, radiologic/histologic findings of diffuse interstitial pneumonitis and/or fibrosis), acute pulmonary reactions (symptoms include fever, chills, cough, chest pain, dyspnea, pulmonary infiltration with consolidation or pleural effusion on x-ray, eosinophilia), pulmonary toxicity (acute and chronic), alveolar infiltrates, alveolar hemorrhage (including fatal cases), interstitial fibrosis, pneumonitis, drug-induced bronchiolitis obliterans with organizing pneumonia
Frequency not reported: Changes in EKG (e.g., nonspecific ST/T wave changes, bundle branch block) associated with pulmonary reactions
Fatalities have been reported with hepatic reactions.
Hepatic toxicity has occurred more often following lengthy therapy (6 months or more) and has presented with jaundice, abdominal pain, malaise, nausea, and anorexia.
Most acute hepatic reactions were self-limiting and resolved within a few days. Patients who experienced chronic reactions often had positive antinuclear antibodies (77%) and may have developed chronic active hepatitis or hepatic necrosis. Liver function tests generally returned to normal after a few months, although deaths due to hepatic failure have been reported.
Hepatotoxicity with concurrent pulmonary effects following the use of nitrofurantoin (the active ingredient contained in Furadantin) has been reported and may be mediated by the immune system. A case of hepatotoxicity accompanied by elevations in serum immune globulins (IgG) has been reported. The authors theorized that cytotoxic T cells (CD8) were involved in the liver damage. They postulated that the antigen-antibody complex was removed when the drug was discontinued as evidenced by the patient's rapidly corrected liver enzyme levels.
Rare (less than 0.1%): Hepatic reactions (including hepatitis, cholestatic jaundice, chronic active hepatitis, hepatic necrosis), hepatotoxicity with concurrent pulmonary reactions
Frequency not reported: Elevated AST (SGOT), elevated ALT (SGPT), elevated bilirubin, hepatic toxicity (presented with jaundice, abdominal pain, malaise, nausea, and anorexia)
Common (1% to 10%): Headache (6%)
Uncommon (0.1% to 1%): Dizziness (less than 1%), drowsiness (less than 1%)
Rare (less than 0.1%):Vertigo, benign intracranial hypertension (pseudotumor cerebri), bulging fontanels
Frequency not reported: Peripheral neuropathy, vertigo, neuropathy (generally beginning as paresthesia of the lower extremities and the hands and progressing to muscle weakness and wasting), cerebellar dysfunction
Peripheral neuropathy (which may become severe or irreversible) has occurred; fatalities have been reported. Risk of peripheral neuropathy may be increased with renal impairment (CrCl less than 60 mL/min or clinically significant elevated serum creatinine), anemia, vitamin B deficiency, diabetes mellitus, electrolyte imbalance, and/or debilitating disease.
Peripheral neuropathy has developed after a few days to several months of therapy. There was no consistent relationship between the dose, length of therapy, and neuropathy development. In a review of 100 cases of peripheral neuropathy, 34 experienced total regression, 45 had partial regression, 13 had no change, and 8 died.
Rare (less than 0.1%): Cyanosis secondary to methemoglobinemia, aplastic anemia
Frequency not reported: Hemolytic anemia, leukopenia, agranulocytosis, granulocytopenia, megaloblastic anemia, eosinophilia, decreased hemoglobin, glucose-6-phosphate dehydrogenase deficiency anemia, thrombocytopenia
Uncommon (0.1% to 1%): Pruritus (less than 1%), urticaria (less than 1%)
Frequency not reported: Lupus-like syndrome associated with pulmonary reactions, angioedema, eruptions (maculopapular, erythematous, and eczematous), anaphylaxis, arthralgia, myalgia, drug fever, chills, vasculitis (sometimes associated with pulmonary reactions)
Postmarketing reports: Hypersensitivity reactions
Hypersensitivity reactions were the most frequently reported side effect during postmarketing experience.
Uncommon (0.1% to 1%): Alopecia (less than 1%)
Rare (less than 0.1%): Exfoliative dermatitis, erythema multiforme (including Stevens-Johnson syndrome)
Frequency not reported: Transient alopecia
Retinopathy due to intraretinal crystals has been reported in a patient with a 9-year history of nitrofurantoin (the active ingredient contained in Furadantin) use.
Uncommon (0.1% to 1%): Amblyopia (less than 1%)
Rare (less than 0.1%): Retinopathy due to intraretinal crystals (at least 1 case)
Frequency not reported: Diplopia, nystagmus
Postmarketing reports: Optic neuritis (rare)
Uncommon (0.1% to 1%): Fever (less than 1%), chills (less than 1%), malaise (less than 1%)
Rare (less than 0.1%): Systemic lupus erythematous-like reactions
Frequency not reported: Asthenia, superinfections due to resistant organisms
Rare (less than 0.1%): Acute interstitial nephritis
Rare (less than 0.1%): Confusion, depression, psychotic reactions
Frequency not reported: Increased serum phosphorus, increased alkaline phosphatase, increased lactate dehydrogenase, increased creatine phosphokinase
Frequency not reported: Dark discoloration of urine
More Furadantin resources
- Furadantin Prescribing Information (FDA)
- Furadantin Advanced Consumer (Micromedex) - Includes Dosage Information
- Furadantin suspension MedFacts Consumer Leaflet (Wolters Kluwer)
- Nitrofurantoin Professional Patient Advice (Wolters Kluwer)
- Nitrofurantoin Monograph (AHFS DI)
- Macrobid Prescribing Information (FDA)
- Macrobid MedFacts Consumer Leaflet (Wolters Kluwer)
- Macrobid Consumer Overview
- Macrodantin Prescribing Information (FDA)
- Macrodantin MedFacts Consumer Leaflet (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.